Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

PRESS RELEASE

Global Agreement Announced at G7 One Health Summit to Accelerate Access to Diagnostics and Responses to Rising Health Threats

Lyon, France (April 7, 2026) —A coalition of more than 20 international partners announced the Global One Health Diagnostics Access Compact (GO-Dx) during the G7 One Health Summit in Lyon, France. This new initiative serves as a catalyst for international leaders across different sectors to advance progress toward expanding diagnostics access, enabling early detection and better surveillance, and improving response against existing and emerging threats across human, animal, and environmental health. By aligning efforts, this group aims to strengthen global preparedness through science based One Health solutions.

Around the world, health authorities are struggling to keep pace with increasingly interconnected threats — from climate-driven shifts that expand the spread of disease carrying species, to rising cases of diseases spilling over from animals to humans, and worsening antimicrobial resistance (AMR). In many regions, the basic ability to test bacteria and other pathogens is scarce or non-existent with information across human, animal, and environmental health remaining siloed and slowing detection. The result is delayed diagnosis, inappropriate treatment, avoidable antibiotic use, compromised patient outcomes, and slower recognition of new pathogens and outbreaks.

As countries refine AMR strategies and prepare upcoming G7 and multilateral commitments, the need for practical, collaborative action is urgent. It is in this context that these partners have developed the GO-Dx Compact — a collective effort to close diagnostic gaps, align action across sectors, and support countries in building more resilient, intelligence-driven health systems.

GO-Dx Compact marks a critical, multi-stakeholder step across the One Health interface toward prioritizing diagnostics access and innovation, bolstering surveillance, and driving antimicrobial stewardship through education and training. By aligning with national and international policy frameworks and advocating for increased public-private collaboration, the Compact aims to increase accurate treatment, reinforce infection-prevention strategies, fortify health systems, and address the rising threat of AMR and other existing and emerging threats.

GO-Dx Partners and Commitments

The Compact is being advanced by a diverse group of partners spanning civil society, private sector, professional and scientific societies, foundations, and global health initiatives committed to One Health and AMR action. Together, they represent tens of thousands of infectious disease and microbiology professionals and support diagnostic, prevention and treatment pathways that reach tens to hundreds of millions of patients each year across health systems in more than 130 countries (find the complete signatories list below).

By endorsing the Compact, the signatories collectively commit to advancing four pillars:

1. Improved Access to Appropriate, High-Quality Diagnostics for All:
   Expand affordable access to priority diagnostics across levels of care and geographies; support data and knowledge sharing to inform public health action.
2. Strengthened Stewardship and Appropriate Use of Diagnostics and Antibiotics:
   Link access to last-line antibiotics with increased diagnostic utilization; integrate diagnostic algorithms and context-relevant AMS training to reinforce diagnostic led decision making.
3. Investment in R&D to Meet Public Health Needs:
   Advance innovation for human, animal, and environmental diagnostics, including solutions contextualized for resource limited settings, through public-private partnerships and open collaboration across industry, academia, NGOs, and public partners.
4. Improved Valuation and Integration of Diagnostics:
   Work with governments, payers, and global partners to ensure diagnostics are appropriately valued, reimbursed, and integrated into clinical and public-health pathways, as well as in animal-health settings, reflecting downstream benefits such as reduced antimicrobial consumption and cost savings.

GO-Dx Compact Next Steps

The Compact signatories commit to advancing this shared effort, recognizing that specific contributions will vary according to individual missions, business models, and areas of work. Each organization will take forward the elements most aligned with its strategic focus while upholding the shared intent of advancing access, stewardship, innovation, and appropriate valuation of diagnostics. Where appropriate, organizations will engage with national governments and multilateral processes, including the G7, to support progress and help ensure diagnostics and surveillance are more systematically reflected in policy commitments, funding mechanisms, and global health strategies.

Access the GO-Dx Compact for full details

Full Partner List:
African Society for Laboratory Medicine, American Society for Microbiology, AMR Action Fund, Bavarian Nordic, bioMérieux, British Society for Antimicrobial Chemotherapy, CARB-X, Ceva Animal Health, Copan Group , Danaher Corporation, DxAMR Collaborative, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, InnotiveDx, International Society of Antimicrobial Chemotherapy, LifeArc, Liofilchem, Nostics, Novo Nordisk Foundation, Roche Diagnostics, Sysmex, Waters Corporation

Media Contacts:

African Society for Laboratory Medicine (ASLM)
Nelly Rwenji
+254 727 228 717
Nrwenji@aslm.org

American Society for Microbiology
Aleea Khan
Akhan@asmusa.org

AMR Action Fund
Chris Sweeney
chris.sweeney@amractio
nfund.com

Bavarian Nordic
Nicole Seroff
VP Corporate Affairs at Bavarian Nordic
Phone: +4553880603
NISE@bavarian￾nordic.com

bioMérieux
Romain Duchez
Tel:+33 (0)4 78 87 20 00
media@biomerieux.com

British Society for Antimicrobial Chemotherapy
Liam Brown
LBrown@BSAC.org.uk

CARB-X
Marissa Novel
carbxpr@bu.edu

Ceva Animal Health
Emilie Barrail
Tel: +33 (0)7 85 61 81 15
emilie.barrail@ceva.com

Copan Group
Barbariga Marco
mob. +39 335 1336617
dir. +39 030 2687211
marco.barbariga@copan
group.com

Danaher Corporation
Mary Carmichael
media@danaher.com

DxAMR Collaborative
Amit Multi
amit.mulji04@imperial.ac.
uk

European Society of Clinical Microbiology and Infectious Diseases
Patrick Kudyba
patrick.kudyba@escmid.or
g

Infectious Diseases Society of America
Jennifer Morales
jmorales@idsociety.org

InnotiveDx
Srijan Jindal
srijan.jindal@innotivedx.co
m

International Society of Antimicrobial Chemotherapy
Dr Fiona MacKenzie
secretariat@isac.world

LifeArc
Andrew Stewart
Andrew.stewart@lifearc.or
g

Liofilchem
Fabio Brocco
+393356272807
fbrocco@liofilchem.com

Nostics
Eva Rennen
Press@nostics.com

Novo Nordisk Foundation
Judith Vonberg
jvo@novo.dk

Roche
Roche Group Media Relations
media.relations@roche.co
m

Sysmex Europe SE
Corporate Communication TeamLead
Ms.Saki Aoyagi
Aoyagi.Saki@sysmex￾europe.com

Waters Corporation
Molly Gluck, Head of External Communications
508.498.9732
PR@waters.com